Q-omics provides the consensus-scored RPL7AP64 profile across patient tissues and cancer cell-line models. RPL7AP64 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, RPL7AP64 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, RPL7AP64 RNA expression shows 13,909 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SKCM, KIRC, and THYM as cancer lineages where RPL7AP64 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL7AP64 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL7AP64 survival associations across molecular data types. RPL7AP64 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL7AP64 RNA expression–survival associations across cancer types. High RPL7AP64 expression shows unfavorable associations in UVM, GBM and LUAD, but favorable associations in SKCM, HNSC and STAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify SKCM as the clearest survival context for RPL7AP64 RNA expression.
This table summarizes RPL7AP64 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL7AP64. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL7AP64 shows lower tumor expression in LUAD, LUSC and THCA and higher tumor expression in KIRC, BRCA and KIRP. The KIRC box plot shows higher RPL7AP64 RNA expression in tumor versus normal tissue (log2 FC = +0.982, t-test p < 0.001).
This table shows molecular features associated with RPL7AP64 in patient tissues and cancer cell lines. In patient samples, RPL7AP64 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
